Alnylam Pharmaceuticals, Inc. (ALNY)
Company Info
Highlights
$33.57B
-$2.10
-0.49
$2.35B
$2.02B
-$152.67M
$144.73 - $304.39
$320.56
3.13%
2.44
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Alnylam Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Alnylam Pharmaceuticals, Inc. (ALNY) returned 9.79% year-to-date (YTD) and 69.64% over the past 12 months. Over the past 10 years, ALNY returned 8.59% annually, underperforming the S&P 500 benchmark at 10.43%.
ALNY
9.79%
15.17%
-5.10%
69.64%
13.72%
8.59%
^GSPC (Benchmark)
-3.70%
13.67%
-5.18%
9.18%
14.14%
10.43%
Monthly Returns
The table below presents the monthly returns of ALNY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 15.30% | -9.05% | 9.43% | -2.51% | -1.86% | 9.79% | |||||||
| 2024 | -9.67% | -12.62% | -1.09% | -3.68% | 3.11% | 63.71% | -2.28% | 10.62% | 4.70% | -3.07% | -5.07% | -7.02% | 22.94% |
| 2023 | -4.73% | -15.44% | 4.63% | -0.56% | -7.12% | 2.66% | 2.87% | 1.24% | -10.47% | -14.29% | 10.84% | 13.77% | -19.46% |
| 2022 | -18.86% | 14.72% | 3.45% | -18.29% | -5.72% | 15.94% | -2.61% | 45.50% | -3.15% | 3.55% | 6.43% | 7.73% | 40.14% |
| 2021 | 15.78% | -1.58% | -4.67% | -0.39% | 0.96% | 19.39% | 5.56% | 12.57% | -6.27% | -15.49% | 15.19% | -7.74% | 30.48% |
| 2020 | -0.33% | 2.50% | -7.49% | 20.99% | 2.71% | 9.49% | -1.59% | -9.00% | 9.77% | -15.54% | 5.64% | 0.05% | 12.85% |
| 2019 | 14.57% | 1.76% | 9.94% | -4.40% | -24.42% | 7.46% | 6.93% | 4.00% | -0.33% | 7.86% | 35.05% | -1.68% | 57.96% |
| 2018 | 2.31% | -7.56% | -0.88% | -20.63% | 5.23% | -0.99% | -3.54% | 29.13% | -28.65% | -8.10% | 0.91% | -10.17% | -42.61% |
| 2017 | 6.81% | 29.13% | -0.76% | 4.59% | 22.13% | 21.85% | 3.74% | 3.61% | 37.05% | 3.70% | 10.42% | -5.57% | 239.34% |
| 2016 | -26.77% | -15.04% | 7.17% | 6.80% | 6.98% | -22.63% | 22.69% | 2.60% | -2.96% | -47.48% | 23.23% | -14.66% | -60.23% |
| 2015 | -3.27% | 8.21% | 2.85% | -2.44% | 28.68% | -8.56% | 6.31% | -19.24% | -21.91% | 6.96% | 21.07% | -9.53% | -2.95% |
| 2014 | 30.11% | -2.89% | -17.36% | -26.23% | 19.71% | 6.54% | -14.33% | 28.73% | 12.10% | 18.75% | 8.42% | -3.53% | 50.86% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 90, ALNY is among the top 10% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Alnylam Pharmaceuticals, Inc. (ALNY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Alnylam Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alnylam Pharmaceuticals, Inc. was 83.58%, occurring on Oct 3, 2011. Recovery took 439 trading sessions.
The current Alnylam Pharmaceuticals, Inc. drawdown is 14.04%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -83.58% | Oct 10, 2007 | 1004 | Oct 3, 2011 | 439 | Jul 3, 2013 | 1443 |
| -77.36% | Jun 23, 2015 | 347 | Nov 3, 2016 | 257 | Nov 10, 2017 | 604 |
| -57.81% | Mar 21, 2018 | 193 | Dec 24, 2018 | 374 | Jun 19, 2020 | 567 |
| -52.18% | Jun 10, 2004 | 46 | Aug 16, 2004 | 100 | Jan 6, 2005 | 146 |
| -47.61% | Jan 14, 2014 | 72 | Apr 28, 2014 | 126 | Oct 24, 2014 | 198 |
Volatility
Volatility Chart
The current Alnylam Pharmaceuticals, Inc. volatility is 17.04%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Alnylam Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Alnylam Pharmaceuticals, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 97.3% positive surprise.
Valuation
The Valuation section provides an overview of how Alnylam Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ALNY compared to other companies in the Biotechnology industry. ALNY currently has a PEG ratio of -0.5. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ALNY relative to other companies in the Biotechnology industry. Currently, ALNY has a P/S ratio of 14.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ALNY in comparison with other companies in the Biotechnology industry. Currently, ALNY has a P/B value of 507.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |